Alkermes Plc (NASDAQ:ALKS) SVP Michael J. Landine sold 25,000 shares of Alkermes stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $33.05, for a total transaction of $826,250.00. Following the transaction, the senior vice president now owns 210,122 shares of the company’s stock, valued at $6,944,532.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of ALKS traded up $0.85 on Friday, hitting $34.02. 43,772 shares of the stock traded hands, compared to its average volume of 830,443. The company has a market capitalization of $5.19 billion, a P/E ratio of -486.00 and a beta of 1.82. The company has a quick ratio of 2.63, a current ratio of 2.89 and a debt-to-equity ratio of 0.24. Alkermes Plc has a one year low of $27.54 and a one year high of $62.42.
Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Thursday, February 14th. The company reported $0.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.39. The company had revenue of $316.00 million during the quarter, compared to the consensus estimate of $255.71 million. Alkermes had a negative net margin of 12.73% and a negative return on equity of 0.49%. The firm’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.31 earnings per share. On average, sell-side analysts expect that Alkermes Plc will post -0.41 EPS for the current year.
Several equities analysts have recently issued reports on ALKS shares. Zacks Investment Research upgraded shares of Alkermes from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a report on Tuesday, January 29th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Alkermes in a report on Thursday, January 10th. ValuEngine lowered shares of Alkermes from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. Goldman Sachs Group lowered shares of Alkermes from a “neutral” rating to a “sell” rating and lowered their target price for the company from $49.00 to $26.00 in a report on Tuesday, December 18th. Finally, BidaskClub upgraded shares of Alkermes from a “hold” rating to a “buy” rating in a report on Saturday, January 12th. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company’s stock. Alkermes has a consensus rating of “Hold” and a consensus target price of $44.15.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
See Also: Ex-Dividend
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.